2016 News Releases

Webcast ImageWebcast - Replay
AtriCure, Inc. at Piper Jaffray 28th Annual Healthcare Conference
11/30/16 at 11:30 a.m. ET
AtriCure, Inc. at Piper Jaffray 28th Annual Healthcare Conference
Wednesday, November 30, 2016 11:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
AtriCure, Inc. at Canaccord Genuity Medical Technologies & Diagnostics Forum
11/17/16 at 2:00 p.m. ET
AtriCure, Inc. at Canaccord Genuity Medical Technologies & Diagnostics Forum
Thursday, November 17, 2016 2:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
AtriCure, Inc. at Stifel 2016 Healthcare Conference
11/15/16 at 9:30 a.m. ET
AtriCure, Inc. at Stifel 2016 Healthcare Conference
Tuesday, November 15, 2016 9:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
11/11/16AtriCure Names Sven Wehrwein to its Board of Directors
MASON, Ohio--(BUSINESS WIRE)--Nov. 11, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Sven Wehrwein has been appointed to its Board of Directors. Mr. Wehrwein has been an independent financial consultant to emerging companies since 1999. He has more than 35 years of experience as an investment banker, chief financ... 
Printer Friendly Version
11/07/16AtriCure to Present at the Piper Jaffray 28th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Nov. 7, 2016-- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Piper Jaffray 28th Annual Healthcare Conference at the Lotte New York Palace Hotel in New York City on Wednesday, November 30, 2016. Management is scheduled to present at 11:30 a.m. Eastern Time. A live audio webcast... 
Printer Friendly Version
11/01/16AtriCure Announces Approval for the cryoICE™ Platform in Japan
Approval adds to the growing portfolio of AtriCure products now available in the Japanese market MASON, Ohio--(BUSINESS WIRE)--Nov. 1, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its cryoICE™ platform and CRYO2 cryoablation ... 
Printer Friendly Version
10/27/16AtriCure Reports Third Quarter 2016 Financial Results
Revenue of $38.3 million – up 22.0% U.S. sales of $30.6 million – up 24.0% International sales of $7.8 million – up 14.9% MASON, Ohio--(BUSINESS WIRE)--Oct. 27, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2016 financial results. “We are pleased to report solid t... 
Printer Friendly Version
10/24/16AtriCure Announces Upcoming Investor Conference Schedule
MASON, Ohio--(BUSINESS WIRE)--Oct. 24, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Stifel Healthcare Conference at the Lotte New York Palace Hotel in New York City on Tuesday, November 15, 2016. Management is scheduled to present at 9:30 a.m. Eastern Time. A live audio webcast of the presentation may be access... 
Printer Friendly Version
10/04/16AtriCure to Announce Third Quarter 2016 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Oct. 4, 2016-- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the third quarter of 2016 on Thursday, October 27, 2016. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, October 27, 2016 to discuss its third quarter 2016 financial results. The call may be accesse... 
Printer Friendly Version
08/18/16AtriCure to Present at the Morgan Stanley Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Aug. 18, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt Hotel in New York City on Wednesday, September 14, 2016. Management is scheduled to present at 11:05 a.m. Eastern Time. A live audio webcast of the presentation may ... 
Printer Friendly Version
08/04/16AtriCure Reports Second Quarter 2016 Financial Results
Revenue of $39.7 million – up 21.8% as reported, 21.5% constant currency U.S. sales of $30.9 million – up 19.9% International sales of $8.8 million – up 28.7% as reported, 27.4% constant currency MASON, Ohio--(BUSINESS WIRE)--Aug. 4, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today annou... 
Printer Friendly Version
07/22/16AtriCure to Present at the Canaccord Genuity Growth Conference
MASON, Ohio--(BUSINESS WIRE)--Jul. 22, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Canaccord Genuity Growth Conference at the Intercontinental Hotel in Boston on Wednesday, August 10, 2016. Management is scheduled to present at 1:30 p.m. Eastern Time. A live audio webcast of the presentation may be accessed by visit... 
Printer Friendly Version
07/11/16AtriCure to Announce Second Quarter 2016 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Jul. 11, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the second quarter of 2016 on Thursday, August 4, 2016. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 4, 2016 to discuss its second quarter 2016 financial results. A live webcast of the c... 
Printer Friendly Version
06/29/16AtriCure Receives CE Mark for the AtriClip® PRO2 Device
CE Mark brings the increased functionality of the AtriClip PRO2 device to the European market for use in managing the left atrial appendage; product was launched in the U.S. in April 2016 MASON, Ohio--(BUSINESS WIRE)--Jun. 29, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received CE Mark for the AtriClip PRO2 Left ... 
Printer Friendly Version
06/21/16AtriCure Announces the First Patient Enrolled in the FROST Cryoanalgesia Study
FROST will evaluate cryoablation of peripheral nerves for the temporary management of post-operative pain MASON, Ohio--(BUSINESS WIRE)--Jun. 21, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient has been enrolled in the FROST study at William Beaumont Hospital, Dearborn, MI. This company-sponsored trial ... 
Printer Friendly Version
05/02/16AtriCure to Present at the UBS Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--May 2, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the UBS Global Healthcare Conference at the Grand Hyatt in New York on Monday, May 23, 2016. Management is scheduled to present at 11:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors p... 
Printer Friendly Version
04/28/16AtriCure Reports First Quarter 2016 Financial Results
Revenue of $35.9 million – up 20.3% as reported, 20.4% constant currency U.S. sales of $28.3 million – up 23.3% International sales of $7.7 million – up 10.1% as reported, 10.9% constant currency MASON, Ohio--(BUSINESS WIRE)--Apr. 28, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced ... 
Printer Friendly Version
04/28/16AtriCure Announces $25 Million Term Loan with Silicon Valley Bank
MASON, Ohio--(BUSINESS WIRE)--Apr. 28, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has entered into an amended and restated term loan and revolving line of credit agreement with Silicon Valley Bank, providing access to a new $25 million five-year term loan, as well as renewing a $15 million revolving line of credit. "We ... 
Printer Friendly Version
04/26/16AtriCure Receives FDA Clearance for New AtriClip® Device
AtriClip PRO2™ LAA Exclusion System features a streamlined hoopless end effector MASON, Ohio--(BUSINESS WIRE)--Apr. 26, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System. The new AtriClip PRO2 system ha... 
Printer Friendly Version
04/12/16AtriCure Announces 510(k) Clearance for the cryoFORM™ Cryoablation Probe
Clearance brings an even more flexible probe to the U.S. market for use in a variety of surgical interventions to treat cardiac arrhythmias; product was launched in Europe in October 2015 MASON, Ohio--(BUSINESS WIRE)--Apr. 12, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received 510(k) clearance for the cryoFORM c... 
Printer Friendly Version
04/05/16AtriCure to Announce First Quarter 2016 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Apr. 5, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the first quarter of 2016 on Thursday, April 28, 2016. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, April 28, 2016 to discuss its first quarter 2016 financial results. A live webcast of the conf... 
Printer Friendly Version
02/23/16AtriCure Reports Fourth Quarter and Full Year 2015 Financial Results
2015 revenue of $129.8 million – up 20.8% as reported, 23.8% constant currency 2015 U.S. sales of $102.2 million – up 27.4% Fourth quarter 2015 revenue of $35.9 million – up 21.9% as reported, 24.0% constant currency MASON, Ohio--(BUSINESS WIRE)--Feb. 23, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, to... 
Printer Friendly Version
02/17/16AtriCure Enrolls First Patient in Randomized Multi-Center Trial Evaluating Post-Operative Afib
This study will evaluate the effects of excluding the LAA in cardiac surgery patients at high risk of developing post-operative Afib WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 17, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, announced today that the first patient was enrolled and treated at PinnacleHealth Hospitals in Harrisburg, Pennsylvania ... 
Printer Friendly Version
02/01/16AtriCure to Announce Fourth Quarter and Full Year 2015 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 1, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the fourth quarter and full year 2015 on Tuesday, February 23, 2016. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, February 23, 2016 to discuss its fourth quarter and full year 2015 financi... 
Printer Friendly Version
01/21/16AtriCure to Present at the Leerink Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 21, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Leerink Global Healthcare Conference at the Waldorf Astoria Hotel in New York on Thursday, February 11, 2016. Management is scheduled to present at 8:05 a.m. Eastern Time. A live audio webcast of the presentation may be accesse... 
Printer Friendly Version
01/19/16AtriCure Announces Approval for the AtriClip in Japan
Approval opens up a new market for the most widely implanted left atrial appendage occlusion device in the world WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 19, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its AtriClip™ product... 
Printer Friendly Version
01/11/16AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2015 Updates 2016 Guidance
MASON, Ohio--(BUSINESS WIRE)--Jan. 11, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced preliminary financial results for fourth quarter and full year 2015 and updated 2016 financial guidance. Preliminary and unaudited revenue for fourth quarter 2015 is expected to be approximately $35.9 million, reflecting growth of approximately 21.9% ... 
Printer Friendly Version